A detailed history of Amalgamated Bank transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 3,769 shares of MRSN stock, worth $6,105. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,769
Previous 3,769 -0.0%
Holding current value
$6,105
Previous $8,000 12.5%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$2.16 - $5.94 $17,273 - $47,502
-7,997 Reduced 67.97%
3,769 $17,000
Q4 2023

Feb 06, 2024

SELL
$1.11 - $2.34 $1,013 - $2,136
-913 Reduced 7.2%
11,766 $27,000
Q2 2023

Aug 11, 2023

BUY
$3.08 - $9.55 $10,127 - $31,400
3,288 Added 35.01%
12,679 $41,000
Q1 2023

May 02, 2023

SELL
$4.0 - $7.02 $9,700 - $17,023
-2,425 Reduced 20.52%
9,391 $39,000
Q4 2022

Feb 10, 2023

BUY
$5.65 - $7.86 $2,062 - $2,868
365 Added 3.19%
11,816 $69,000
Q3 2022

Nov 09, 2022

BUY
$4.63 - $8.0 $1,463 - $2,528
316 Added 2.84%
11,451 $77,000
Q2 2022

Aug 15, 2022

BUY
$2.84 - $5.0 $979 - $1,725
345 Added 3.2%
11,135 $51,000
Q1 2022

Jun 30, 2022

SELL
$3.74 - $6.63 $3,164 - $5,608
-846 Reduced 7.27%
10,790 $43,000
Q4 2021

Feb 15, 2022

SELL
$5.48 - $9.86 $1,172 - $2,110
-214 Reduced 1.81%
11,636 $72,000
Q3 2021

Oct 29, 2021

SELL
$8.56 - $14.47 $1,463 - $2,474
-171 Reduced 1.42%
11,850 $112,000
Q2 2021

Aug 16, 2021

BUY
$13.28 - $18.07 $159,638 - $217,219
12,021 New
12,021 $163,000
Q1 2021

May 13, 2021

SELL
$15.31 - $26.52 $127,440 - $220,752
-8,324 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$16.84 - $27.59 $140,176 - $229,659
8,324 New
8,324 $221,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $157M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.